StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Stock analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Several other analysts have also recently commented on VNRX. HC Wainwright began coverage on shares of VolitionRx in a research report on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price for the company. D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, VolitionRx currently has an average rating of “Hold” and a consensus target price of $3.33.

VolitionRx Price Performance

VNRX opened at $0.49 on Monday. The firm has a 50 day simple moving average of $0.55 and a 200 day simple moving average of $0.62. VolitionRx has a fifty-two week low of $0.42 and a fifty-two week high of $1.02. The company has a market cap of $49.37 million, a price-to-earnings ratio of -1.36 and a beta of 1.15.

Insiders Place Their Bets

In related news, CEO Cameron John Reynolds acquired 181,818 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $0.55 per share, with a total value of $99,999.90. Following the transaction, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. The trade was a 8.59 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the last quarter. Two Sigma Securities LLC acquired a new position in VolitionRx in the 4th quarter valued at about $29,000. Northern Trust Corp raised its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Lagoda Investment Management L.P. boosted its position in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Finally, Millennium Management LLC acquired a new stake in VolitionRx during the fourth quarter worth approximately $36,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.